Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26330807 | 0.82 | GRIN2B (0.51) | DRD3DRD2DRD4MGLL | |
| SCHEMBL26331459 | 0.81 | HSD11B1 (0.68) | HSD11B1MAPTPOLBALDH1A1MGLL | |
| SCHEMBL26330814 | 0.80 | ALDH1A1 (0.50) | POLBMEN1ALDH1A1KMT2A | |
| SCHEMBL13503783 | 0.78 | HSD11B1 (0.63) | HSD11B1MAPTPOLBKDM4EMEN1 | |
| SCHEMBL26330809 | 0.78 | ALDH1A1 (0.52) | POLBMEN1ALDH1A1KMT2A | |
| SCHEMBL21381650 | 0.77 | SLC6A3 (0.51) | HSD11B1MAPTMGLL | |
| SCHEMBL7328218 | 0.76 | SLC6A3 (0.53) | HSD11B1MAPTMGLL | |
| SCHEMBL11712337 | 0.76 | SLC6A3 (0.50) | HSD11B1MAPTKMT2AMGLL | |
| SCHEMBL3977616 | 0.74 | HSD11B1 (0.65) | HSD11B1POLBKDM4EMEN1ALDH1A1 | |
| SCHEMBL10667527 | 0.73 | CYP2D6 (0.54) | HSD11B1MAPTDRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286982-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSME1, PSME4 | HSD11B1 2648/4885MAPT 139/4885DRD3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.